Charles Robb serves as the Chief Business Officer at Corcept Therapeutics Inc., a position that leverages his extensive experience in the biopharmaceutical industry. Robb joined Corcept in 2013 and has been instrumental in steering the company's strategic direction, particularly in the commercialization and development of treatments for severe metabolic, oncologic, and psychiatric disorders. Prior to his role at Corcept, Robb held various leadership positions at major pharmaceutical companies, including Bayer HealthCare and Genentech, where he honed his skills in business development, marketing, and strategic planning. At Corcept Therapeutics, Robb has played a key role in the successful launch and market expansion of the company's flagship product, Korlym, used for the treatment of Cushing's syndrome. Under his guidance, Corcept has not only solidified its position in the market but also expanded its research and development pipeline, focusing on new indications for Korlym and other promising compounds. His strategic vision has been crucial in forging key partnerships and collaborations that have enhanced the company's growth and innovation capabilities. Robb's professional achievements extend beyond his tenure at Corcept. At Bayer HealthCare, he was recognized for his leadership in driving the successful global launch of several blockbuster products. His time at Genentech was marked by his contributions to the oncology division, where he helped develop and execute strategies that significantly increased market share. Robb's comprehensive understanding of the pharmaceutical landscape, combined with his ability to navigate complex regulatory environments, makes him a vital asset to Corcept Therapeutics as they continue to advance their mission of improving patient outcomes through innovative therapies.